Orthocell (ASX:OCC) received regulatory clearance from the US Food and Drug Administration for its nerve repair product, Remplir, under the 510(k) pathway, allowing sales in the US market, according to a Friday filing with the Australian bourse.
Products delivered to the US will be manufactured at the company's Western Australia facility, the filing said.
Remplir is approved for sale in Australia, New Zealand, and Singapore, with pending approvals in Canada and Thailand in the next six months, according to the filing.
Shares were down 4% in morning trade Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。